Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals appoints Matt David as chief financial officer

Neutral Impact 4 of 5 leadership Written later

Actinium Pharmaceuticals said Matt David, M.D., began serving as chief financial officer on October 14, 2026, succeeding no one named in the filing. He previously was chief financial officer of CorMedix Inc. and will lead finance, accounting, capital markets and investor relations.

Key points

  • Dr. David commenced service as CFO and principal financial officer on October 14, 2026, under an offer letter dated September 30, 2026.
  • Offer terms include a $450,000 annual base salary, a 40% target annual bonus, and a $150,000 sign-on bonus.
  • He received an option on 250,000 shares and 325,000 restricted stock units under the 2026 Employment Inducement Award Plan, adopted by the Board on September 2, 2026 without stockholder approval.

The filing

CompanyActinium Pharmaceuticals, Inc. (ATNM)
Form8-K, current report
Filed with the SECOct 15, 2026, 5:05 PM ET
Accession number0001213900-26-109884

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.